CYTOKINETICS director exercises 5,175 options, sells 5,175 shares

Cytokinetics (CYTK) filed a Form 4 reporting insider activity.

Rhea-AI Filing Summary

Cytokinetics (CYTK) filed a Form 4 reporting insider activity. On 11/11/2025, a director exercised 5,175 stock options at $9.66 per share (code M), then sold 5,175 shares at $65.08 (code S). After these transactions, the director beneficially owned 9,977 shares, held directly.

The exercised options were non-qualified options originally exercisable beginning 08/01/2016 and expiring 07/01/2026, covering 5,175 underlying common shares.

Insider Trade Summary

Exercise and Sale: 5,175 shares ($287K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Kaye Edward M. MD

Role Director

Sold 5,175 shs ($337K)

Approx. gross sale proceeds $337K

Approx. exercise cost $50K

Approx. pre-tax spread $287K

Type	Security	Shares	Price	Value
Exercise	Non-Qualified Stock Option (Right to Buy)	5,175	$0.00	$0.00
Exercise	Common Stock	5,175	$9.66	$50K
Sale	Common Stock	5,175	$65.08	$337K

Holdings After Transaction: Non-Qualified Stock Option (Right to Buy) — 0 contracts (Direct); Common Stock — 9,977 shares (Direct)

Footnotes (1)

1. F1. This option shall vest and become exercisable as to 5,175 shares divided into equal monthly installments such that the option shall be 100% vested on January 1, 2017.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CYTOKINETICS (CYTK) report?

A director exercised 5,175 options at $9.66 and sold 5,175 shares at $65.08 on 11/11/2025.

How many CYTK shares does the insider hold after the transactions?

Following the transactions, the insider beneficially owned 9,977 shares, held directly.

What was the exercise price and type of the derivative security?

Non-qualified stock option with an exercise price of $9.66 per share.

At what price were the CYTK shares sold?

The reported sale price was $65.08 per share.

When were the options originally exercisable and when do they expire?

Exercisable beginning 08/01/2016; expiration on 07/01/2026.

What is the insider’s relationship to CYTOKINETICS?

The reporting person is a Director of CYTOKINETICS.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/12/2025 - 06:50 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kaye Edward M. MD

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/11/2025		M		5,175	A	$9.66	15,152	D
Common Stock	11/11/2025		S		5,175	D	$65.08	9,977	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (Right to Buy)	$9.66	11/11/2025		M			5,175	08/01/2016(1)	07/01/2026	Common Stock	5,175	$0	0	D

Explanation of Responses:

1. This option shall vest and become exercisable as to 5,175 shares divided into equal monthly installments such that the option shall be 100% vested on January 1, 2017.

	/s/ John Faurescu, attorney-in-fact for Dr. Kaye	11/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.